GlassScriptPhysician profile
Mark R Henschke
NPI 1922092667
$113,816.94
in general payments reported to CMS, 2019-2025
28 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,025 · 2020: $21K · 2021: $43K · 2022: $33K · 2023: $6,843 · 2024: $2,558 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,325 · Food and Beverage: $927 · Travel and Lodging: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,325.00 |
| Food and Beverage | $927.37 |
| Travel and Lodging | $580.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82,096.24 | 2019-2024 | |
| Allergan, INC. | $22,280.11 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $4,780.25 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $883.85 | 2019-2021 | |
| Glaxosmithkline, LLC. | $799.40 | 2019-2024 | Nucala |
| Astrazeneca Pharmaceuticals LP | $613.50 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.98 | 2020-2023 | Jardiance, Synjardy |
| Teva Pharmaceuticals USA, INC. | $265.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $203.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $176.48 | 2019-2023 | Verquvo |
| Amgen INC. | $167.53 | 2021-2025 | Tepezza |
| Genentech USA, INC. | $143.31 | 2019 | |
| Radius Health, INC. | $125.01 | 2019 | |
| Alexion Pharmaceuticals, INC. | $124.97 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.13 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $121.09 | 2025 | Auvelity |
| Portola Pharmaceuticals, LLC | $98.34 | 2019 | |
| Pfizer INC. | $98.09 | 2019-2024 | |
| Lilly USA, LLC | $93.74 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $90.80 | 2021 | |
| Novo Nordisk INC | $69.52 | 2019-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $41.65 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $22.32 | 2024 | Evkeeza |
| Antares Pharma, INC. | $19.57 | 2023 | Tlando, Xyosted, Nocdurna |
| Phathom Pharmaceuticals, INC. | $17.29 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.07 | 2019 | |
| Exact Sciences Corporation | $13.93 | 2023 | Cologuard Collection Kit |
| Corium, LLC | $10.69 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Henschke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.